Table 3.
Associations between CEoEC sites and initial treatment
| Treatment approach | OR | aORa |
|---|---|---|
| Dietary elimination | ||
|
| ||
| Chapel Hill, NC | Referent | Referent |
| Charlotte, NC | 26.456 (7.839–89.285) | 7.201 (1.796–28.877) |
| Greenville, SC | >999.999 (407.898 to >999.999) | >999.999 (272.363 to >999.999) |
| Charleston, SC | 5.728 (1.210–27.109) | 2.651 (0.503–13.984) |
| Winston-Salem, NC | 11.048 (2.239–54.520) | 2.776 (0.430–17.908) |
|
| ||
| Combination | ||
|
| ||
| Chapel Hill, NC | Referent | Referent |
| Charlotte, NC | 2.326 (1.062–5.095) | 0.902 (0.326–2.494) |
| Greenville, SC | 115.988 (14.160–950.108) | 106.882 (12.003–951.726) |
| Charleston, SC | 7.058 (3.218–15.480) | 4.926 (1.900–12.769) |
| Winston-Salem, NC | 8.286 (3.284–20.903) | 3.900 (1.100–13.829) |
aOR is the adjusted odds of treatment as compared with the referent treatment (topical steroids), for a given site as compared with the referent site (Chapel Hill), adjusting on baseline patient factors. aOR, adjusted odds ratio; CEoEC, Carolinas EoE Collaborative; EoE, eosinophilic esophagitis; eos, eosinophils; hpf, hpf, high power field; OR, odds ratio.
a
Adjusted for insurance, atopic disease, date of diagnosis, and maximum eos/hpf at baseline.
**
Multinomial model assessing study site in relation to baseline treatment approach. A